[go: up one dir, main page]

WO1997010818A1 - Method and composition for treating mammalian diseases caused by inflammatory response - Google Patents

Method and composition for treating mammalian diseases caused by inflammatory response Download PDF

Info

Publication number
WO1997010818A1
WO1997010818A1 PCT/US1996/014304 US9614304W WO9710818A1 WO 1997010818 A1 WO1997010818 A1 WO 1997010818A1 US 9614304 W US9614304 W US 9614304W WO 9710818 A1 WO9710818 A1 WO 9710818A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyruvate
composition
lactate
inflammatory mediator
precursor
Prior art date
Application number
PCT/US1996/014304
Other languages
French (fr)
Inventor
Stanley E. Katz
Original Assignee
Cellular Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences, Inc. filed Critical Cellular Sciences, Inc.
Priority to MX9703653A priority Critical patent/MX9703653A/en
Priority to JP51274197A priority patent/JP4459303B2/en
Priority to CA002205112A priority patent/CA2205112C/en
Priority to AU69159/96A priority patent/AU719332B2/en
Priority to EP96929932A priority patent/EP0804181A4/en
Priority to NZ306832A priority patent/NZ306832A/en
Publication of WO1997010818A1 publication Critical patent/WO1997010818A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention pertains to therapeutic methods of preventing and treating the damage and resulting disease state in mammals caused by mammalian cells involved in the inflammatory response resulting in undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
  • This invention also pertains to compositions used in the therapeutic methods.
  • Reactive oxygen species are generated by cells in response to inter alia aerobic metabolism, catabolism of drugs, toxins and other xenobiotics.
  • ultraviolet and x-ray radiation and the respiratory burst of phagocytic cells (such as white blood cells) to kill invading bacteria and in response to foreign bodies.
  • Hydrogen peroxide for example, is produced during respiration of most living organisms especially by stressed and living cells.
  • lipid peroxidation which involves the oxidative degradation of unsaturated lipids.
  • Lipid peroxidation is highly detrimental to membrane structure and function and can cause numerous cytopathological effects.
  • Cells defend against lipid peroxidation by producing radical scavengers such as superoxide dismutase, catalase, and peroxidase. Injured cells have a decreased ability to produce radical scavengers.
  • Excess hydrogen peroxide can react with pyrimidines to open the 5, 6- double bond. This reaction inhibits the ability of pyrimidines to hydrogen bond to complementary bases, Hallaender et al. ( 1971 ).
  • Such oxidative biochemical injury can result in the loss of cellular membrane integrity, reduced enzyme activity, changes in transport kinetics, changes in membrane lipid content, and leakage of potassium ions, amino acids, and other cellular material.
  • the production of reactive oxygen intermediates has been suggested to cause many skin, tissue, and organ disorders such as atherosclerosis, arthritis, cytotoxicity, skin inflammation, photoaging, wrinkling, actinic keratosis, tumor formation, cancer, hypertension, Parkinson's disease, lung disease, and heart disease.
  • the role of active oxygen radicals in promoting tumors has been proposed based on the findings that (a) tumor promoters increase the level of oxygen radicals, (b) many free radical generating systems promote tumors, and (c) certain antioxidants inhibit the biochemical effects of tumor promoters.
  • reactive oxygen intermediates can be generated in cellular culture media by autooxidation and photooxidation of media components.
  • transplant organs can suffer oxidative injuries which result in thee loss of cellular membrane integrity and shorten the usable life ofthe organ.
  • United States Patent No. 5,210,098 issued to Nath discloses a method to arrest or prevent acute kidney failure by administration of a non-toxic pyruvate salt to a patient in need of such treatment.
  • the Nath invention provides a therapeutic method comprising administration of an amount of pyruvate salt to a patient experiencing, or in danger of, acute renal failure.
  • the pyruvate salt preferably sodium pyruvate
  • the pyruvate salt is preferably dispersed or dissolved in a pharmaceutically acceptable liquid carrier and administered parenterally in an amount effective to arrest or prevent said acute renal failure, thus permitting restoration of normal kidney function.
  • the pyruvate may be infused directed into the kidney or into the proximal renal arterial circulation.
  • the method is effective to prevent or counteract acute kidney failure due to a wide variety of causes, including, but not limited to, traumatic injury, including burn injury and obstruction; reperfusion following ischemia, inflammatory glomerulonephritis, and sepis, e.g. due to gram negative bacterial infection.
  • the therapeutic composition comprises (a) pyruvate selected from the group consisting of pyruvic acid, pharmaceutically acceptable salts of pyruvic acid, and mixtures thereof, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids wherein the fatty acids are those fatty acids required for the resuscitation of injured mammalian cells.
  • United States Patent No. 5,256,697 issued to Miller et al.. discloses a method for orally administering a therapeutically effective amount of pyruvate precursor to a mammal to improve insulin resistance, lower lasting insulin levels and reduce fat gain.
  • United States patent nos. 3,920,835, 3,984,556, and 3,988,470 all issued to Van Scott et al. disclose methods for treating acne, dandruff, and palmar keratosis, respectively, which consist of applying to the affected area a topical composition comprising from about 1% to about 20% ofa lower aliphatic compound containing from two to six carbon atoms selected from the group consisting of alpha-hydroxyacids, alpha-ketoacids and esters thereof, and 3-hydroxybutryic acid in a pharmaceutically acceptable carrier.
  • the aliphatic compounds include pyruvic acid and lactic acid.
  • United States patents nos. 4,105,783 and 4,197,316, both issued to Yu et al.. disclose a method and composition, respectively, for treating dry skin which consists of applying to the affected area a topical composition comprising from about 1% to about 20% ofa compound selected from the group consisting of amides and ammonium salts of alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier.
  • the compounds include the amides and ammonium salts of pyruvic acid and lactic acid.
  • United States patent no.4,234,599 issued to Van Scott et al. discloses a method for treating actinic and nonactinic skin keratoses which consists of applying to the affected area a topical composition comprising an effective amount of a compound selected from the group consisting of alpha-hydroxyacids, beta- hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier.
  • the acidic compounds include pyruvic acid and lactic acid.
  • United States patent no. 4,294,852 issued to Wildnauer et al.. discloses a composition for treating skin which comprises the alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids disclosed above by Van Scott et al. in combination with C3-C8 aliphatic alcohols.
  • United States patent no. 4,663,166 issued to Veech, discloses an electrolyte solution which comprises a mixture of L-lactate and pyruvate in a ratio from 20:1 to 1 :1, respectively, or a mixture of D-beta-hydroxybutyrate and acetoacetate, in a ratio from 6: 1 to 0.5:1 , respectively.
  • Sodium pyruvate has been reported to reduce the number of erosions, ulcers, and hemorrhages on the gastric mucosa in guinea pigs and rats caused by acetylsalicylic acid.
  • the analgesic and antipyretic properties of acetylsalicylic acid were not impaired by sodium pyruvate, Puschmann, Arzneistoffforschung. 33. pp.
  • Pyruvate has been reported to produce a relative stabilization of left ventricular pressure and work parameter and to reduce the size of infarctions. Pyruvate improves resumption of spontaneous beating ofthe heart and restoration of normal rates and pressure development, Bunger et al., J. Mol. Cell. Cardiol.. 18. pp. 423-438 (1986), Mochizuki et al.. J. Phvsiol. (Paris). 76, pp. 805-812 (1980), Regitz et al.. Cardiovasc. Res.. 15 pp. 652-658 (1981), Giannelli et al.. Ann.Thorac. Sure.. 21 pp. 386-396. (1976).
  • Sodium pyruvate has been reported to act as an antagonist to cyanide intoxication (presumably through the formation of cyanohydrin) and to protect against the lethal effects of sodium sulfide and to retard the onset and development of functional, mo ⁇ hological, and biochemical measures of acrylamide neuropathy of axons, Schwartz et aL, Toxicol. Appl. Pharmacol., 50 pp. 437-442 ( 1979), Sabri et al. Brain Res.. 483. pp. 1-11 (1989).
  • a chemotherapeutic cure of advanced L1210 leukemia has been reported using sodium pyruvate to restore abnormally deformed red blood cells to normal. The deformed red blood cells prevented adequate drug delivery to tumor cells. Cohen. Cancer Chemother. Pharmacol.. 5. pp. 175-179 (1981).
  • United States patents nos. 4,158,057, 4,351,835, 4,415,576, and 4,645,764, all issued to Stanko disclose methods for preventing the accumulation of fat in the liver ofa mammal due to the ingestion of alcohol, for controlling weight in a mammal, for inhibiting body fat while increasing protein concentration in a mammal, and for controlling the deposition of body fat in a living being, respectively.
  • the methods comprise administering to the mammal a therapeutic mixture of pyruvate and dihydroxyacetone, and optionally riboflavin.
  • United States patent no.4,548,937 discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of pyruvate, and optionally riboflavin.
  • United States patent no 4,812,479, issued to Stanko discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of dihydroxyacetone, and optionally riboflavin and pyruvate.
  • Rats fed a calcium-oxalate lithogenic diet including sodium pyruvate were reported to develop fewer urinary calculi (stones) than control rats not given sodium pyruvate, Ogawa et al.. Hinvokika Kivo. 32, pp. 1341-1347 (1986).
  • United States patent no. 4,521,375 discloses a method for sterilizing surfaces which come into contact with living tissue. The method comprises sterilizing the surface with aqueous hydrogen peroxide and then neutralizing the surface with pyruvic acid.
  • United States patent no. 4,416,982 issued to Tauda et al.. discloses a method for decomposing hydrogen peroxide by reacting the hydrogen peroxide with a phenol or aniline derivative in the presence of peroxidase.
  • United States patent no, 4,696,917, issued to Lindstrom et al. discloses an irrigation solution which comprises Eagle's Minimum Essential Medium with Earle's salts, chondroitin sulfate, a buffer solution, 2-mercaptoethanol, and a pyruvate.
  • the irrigation solution may optionally contain ascorbic acid and alpha-tocopherol.
  • United States patent no. 4,725,586, issued to Lindstrom et al.. discloses an irrigation solution which comprises a balanced salt solution, chondroitin sulfate, a buffer solution, 2 mercaptoethanol, sodium bicarbonate or dextrose, a pyruvate, a sodium phosphate buffer system, and cystine.
  • the irrigation solution may optionally contain ascorbic acid and gamma-tocopherol.
  • United States patent no. 4,847,069, issued to Bissett et al.. discloses a photoprotective composition comprising (a) a sorbohydroxamic acid, (b) an anti ⁇ inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier. Fatty acids may be present as an emollient.
  • United States patent no. 4,847,071, issued to Bissett et al.. discloses a photoprotective composition comprising (a) a tocopherol or tocopherol ester radical scavenger, (b) an anti-inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier.
  • United States patent no. 4,847,072, issued to Bissett et al.. discloses a topical composition comprising not more than 25% tocopherol sorbate in a topical carrier.
  • compositions and methods are reported to inhibit the production of reactive oxygen intermediates, none ofthe compositions and methods treats the damage and resulting disease state in mammals caused by undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
  • the present invention pertains to a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response and compositions useful in the method.
  • the method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response comprises: contacting the mammalian cells participating in the inflammatory response with an inflammatory mediator; wherein the inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant.
  • the inflammatory mediator in addition to reducing the undesired inflammatory response and being an antioxidant, may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components.
  • the inflammatory mediator may also increase cellular metabolic rate.
  • the present invention also pertains to compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprising: An inflammatory response mediator; and a carrier composition; wherein the inflammatory response mediator is an antioxidant and capable of reducing undesired inflammatory response in mammalian cells.
  • the inflammatory response mediators may be used individually, in combination and further in combination with a therapeutic agent such as an antibacterial, antiviral, antifungal, protein, enzyme, antihistamine, hormone, nonsteroidal anti-inflammatory, cytokine, and steroid.
  • a therapeutic agent such as an antibacterial, antiviral, antifungal, protein, enzyme, antihistamine, hormone, nonsteroidal anti-inflammatory, cytokine, and steroid.
  • a preferred method of administering the inflammatory mediator is by inhalation.
  • compositions and a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response have been discovered.
  • the mammalian cells primarily responsible for the inflammatory response are white blood cells or leucocytes.
  • mammalian cells are contacted with an inflammatory mediator.
  • the inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant.
  • the inflammatory response is the response of defensive mammalian cells primarily white blood cells or leucocytes. These cells normally respond to an injury or invasion ofthe mammal by releasing a number of active compounds at the injury or invasion site. Among the compounds released are enzymes such as proteases and active oxygen species such as hydrogen peroxide.
  • a purpose ofthe respiratory burst is to provide a battery of oxidizing agents in response to a stimulant that can be used by the leucocytes for the destruction of foreign cells, viruses, particulates and some toxins which have been ingested by or are in the vicinity of the leucocyte.
  • the term "respiratory burst" refers to a coordinated series of metabolic events that take place when leucocytes are exposed to appropriate stimuli. This group of events underlies all oxygen dependent killings by leucocytes.
  • the first of these events is the sharp increase in oxygen uptake that occurs upon stimulation ofthe leucocytes. While oxygen consumption by resting leucocytes varies widely by cell type, all respond to appropriate stimuli with an increase in oxygen uptake.
  • Stimulation of the leucocyte also causes an increase in glucose oxidation via the hexose monophosphate shunt.
  • the hexose monophosphate shunt is a metabolic pathway in which glucose is oxidized to carbon dioxide and a five carbon sugar, with NADP+ serving as electron acceptor.
  • Activation ofthe hexose monophosphate shunt therefore means that the oxidation of NADPH to NADP+ increases during the respiratory burst.
  • the respiratory burst produces superoxide and hydrogen peroxide.
  • Oxygen taken up by the respiratory burst is converted to superoxide. Hydrogen peroxide appears to arise during the respiratory burst mainly from the dismutation of superoxide anion.
  • Invest. 60: 1266 that 80 percent ofthe superoxide is converted to hydrogen peroxide, and this dismutation reaction is the only important source of the hydrogen peroxide generated during the burst. Hydrogen peroxide and superoxide are believed to be responsible for the killing by leucocytes. Many agents, both soluble and particulate, are able to activate the respiratory burst. Particulate activating agents include bacteria, viruses and fungi for internal body organs or areas and bacteria, viruses, fungi, fibers, smoke, dust, ash, pollen, smog and the like for body cavities and organs such as the lungs, skin, digestive and excretory tracks open to the environment. Soluble agents can be toxins, medicinal compounds and soluble excretions of bacteria, fungi and infected mammalian cells and the like.
  • leucocytes as used herein includes lymphocytes, phagocytes, macrophages and auxiliary cells.
  • the stimulant and/or the mechanism of stimulation turns off allowing the leucocyte to return to its normal resting state.
  • the inflammatory action of the leucocytes continues unchecked causing a number of disease states.
  • These disease states occur as the compounds produced by the leucocytes attack, injure and kill tissue cells and other leucocytes. It is this failure to turn off the respiratory burst and the resulting injury to surrounding tissue cells, blood cells, other leucocytes and injured cells that produces the disease states treated by the present invention.
  • Undesired inflammatory response occurs when the inflammatory response causes injury to host cells and this injury poses an independent threat to the host.
  • the therapeutic compositions containing an inflammatory mediator are administered locally to the site of inflammation.
  • the therapeutic compositions are administered systemically.
  • the therapeutic compositions are administered systemically and locally concomitantly.
  • the therapeutic compositions are administered by inhalation.
  • the therapeutic compositions may be first nebulized by any suitable means.
  • the therapeutic compositions may be in liquid or solid form with liquid droplets or particle size being small enough to facilitate access to lung tissue by inhalation.
  • a sterile solution of therapeutic agent is nebulized and inhaled by the patient.
  • a therapeutically effective amount of inflammatory medication is inhaled. This may be accomplished in a single inhalation or by repeated inhalations over a period of time typically 1 to 30 minutes.
  • inhalation will be complete in less than 20 minutes. Most preferably inhalation will be complete in less than 15 minutes.
  • injured cell means a cell which has some or all of the following: (a) injured membranes so that transport through the membranes is diminished and may result in one or more of the following, an increase in toxins and normal cellular wastes inside the cell and/or a decrease in nutrients and other components necessary for cellular repair inside the cell, (b) an increase in concentration of oxygen radicals inside the cell because ofthe decreased ability of the cell to produce antioxidants and enzymes, and (c) damaged DNA, RNA and ribosomes which must be repaired or replaced before normal cellular functions can be resumed.
  • the inflammatory mediator when brought into contact with a mammalian cell provides a cellular energy source and a building block in the cellular synthesis of other cellular components.
  • the inflammatory response being reduced is at least one of the following: oxygen radical production, peroxide production, cytokine and/or protease production, prostiglandin production, erythema, histamine and interlukin production and like responses known in the art as inflammatory responses.
  • the preferred inflammatory mediator is at least one compound selected from the group consisting of a pyruvate precursor, pyruvate, a lactate precursor and lactate.
  • a precursor is a substance from which another substance is formed and in this text also includes salts.
  • the pyruvate is selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and the like and mixtures thereof.
  • Sodium pyruvate is most preferred.
  • Another preferred inflammatory mediator is selected from the group consisting of pyruvy 1- gly cene, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, dihydroxyacetone, and propylene glycol.
  • Preferred salts of the inflammation mediator are salts that do not produce an adverse effect on the mammalian cell when applied as a salt of the inflammation mediator.
  • Typical salts would be the lithium, sodium, potassium, aluminum, magnesium, calcium, zinc, manganese, ammonium and the like and mixtures thereof.
  • the lactate precursor is preferably selected from the group consisting of lactyl-glycene, lactyl-alanine, lactyl-leucine, lactyl-valine, lactyl-isoleucine, lactyl-phenylalanine, lactamide and the various salts of lactate.
  • compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprise: an inflammatory response mediator; and a carrier composition.
  • the carrier composition is selected from the group consisting of tablets, capsules, liquids, isotonic liquids, isotonic media, enteric tablets and capsules, parenterals, topicals, creams, gels, ointments, chewing gums, confections and the like.
  • the inflammatory mediator is administered in a therapeutically effective amount to reduce the undesired inflammatory response. Preferably from 0.001 to 10 grams per dose. More preferably 0.001 to 1 gram per dose and most preferably 0.001 to 0.25 grams per dose. It is understood that the method of administration and the condition being treated will greatly affect the dose required to achieve the therapeutic effect.
  • Typical airway diseases treatable by the present compositions and method include but are not limited to bronchial asthma, acute bronchitis, emphysema, chronic obstructive emphysema, centrilobular emphysema, panacinar emphysema, chronic obstructive bronchitis, reactive airway disease, cystic fibrosis, bronchiectasis, acquired bronchiectasis, kartaagener's syndrome, atelectasis, acute atelectasis, chronic atelectasis, pneumonia, essential thrombocytopenia, legionnaires disease, psittacosis, fibrogenic dust disease, diseases due to organic dust, diseases due to irritant gases and chemicals, hypersensitivity diseases ofthe lung, idiopathic infiltrative diseases ofthe lungs and the like. Particular disease states to be treated are emphysema and asthma.
  • the inflammatory mediator of the present invention may be administered prior to, after and/or with other therapeutic agents.
  • Typical therapeutic agents are antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti-inflammatories, cytokines, steroids, and the like.
  • Treatment was conducted as follows: Five (5) milliliters of five (5) millimolar sodium pyruvate solution is filter sterilized through a 0.2 micron filter. The sterile pyruvate solution is placed into a "Pulmo Aid" nebulizer manufactured by DeVilbiss Co., Somerset, Pennsylvania 15501-0635.
  • the sterile pyruvate solution is nebulized by the Pulmo Aid device fitted with a disposable nebulizer and inhaled by the patient.
  • the patient inhales normally from the Pulmo Aid nebulizer until all of the solution has been nebulized and inhaled. This inhalation step typically takes about ten (10) to twenty (20) minutes.
  • the patient is treated with this inhalation therapy periodically. Initially, treatments are about four (4) times a day at about six (6) hour intervals. Treatments were reduced to three (3) times a day at about eight (8) hour intervals after 30 days of therapy. Treatments were further reduced to once a day 60 DAYS AFTER ONSET OF TREATMENT. After ninety (90) days treatments are three to five times a week.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

Description

METHOD AND COMPOSITION FOR
TREATING MAMMALIAN DISEASES CAUSED
BY INFLAMMATORY RESPONSE
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention pertains to therapeutic methods of preventing and treating the damage and resulting disease state in mammals caused by mammalian cells involved in the inflammatory response resulting in undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
This invention also pertains to compositions used in the therapeutic methods.
Description of the Prior Art
Reactive oxygen species are generated by cells in response to inter alia aerobic metabolism, catabolism of drugs, toxins and other xenobiotics. ultraviolet and x-ray radiation and the respiratory burst of phagocytic cells (such as white blood cells) to kill invading bacteria and in response to foreign bodies. Hydrogen peroxide, for example, is produced during respiration of most living organisms especially by stressed and living cells.
These active oxygen species can injure cells. An important example of such damage is lipid peroxidation which involves the oxidative degradation of unsaturated lipids. Lipid peroxidation is highly detrimental to membrane structure and function and can cause numerous cytopathological effects. Cells defend against lipid peroxidation by producing radical scavengers such as superoxide dismutase, catalase, and peroxidase. Injured cells have a decreased ability to produce radical scavengers. Excess hydrogen peroxide can react with pyrimidines to open the 5, 6- double bond. This reaction inhibits the ability of pyrimidines to hydrogen bond to complementary bases, Hallaender et al. ( 1971 ). Such oxidative biochemical injury can result in the loss of cellular membrane integrity, reduced enzyme activity, changes in transport kinetics, changes in membrane lipid content, and leakage of potassium ions, amino acids, and other cellular material.
The production of reactive oxygen intermediates has been suggested to cause many skin, tissue, and organ disorders such as atherosclerosis, arthritis, cytotoxicity, skin inflammation, photoaging, wrinkling, actinic keratosis, tumor formation, cancer, hypertension, Parkinson's disease, lung disease, and heart disease. The role of active oxygen radicals in promoting tumors has been proposed based on the findings that (a) tumor promoters increase the level of oxygen radicals, (b) many free radical generating systems promote tumors, and (c) certain antioxidants inhibit the biochemical effects of tumor promoters.
In Vitro, reactive oxygen intermediates can be generated in cellular culture media by autooxidation and photooxidation of media components. During excision and storage, transplant organs can suffer oxidative injuries which result in thee loss of cellular membrane integrity and shorten the usable life ofthe organ.
When cells are stressed by oxidative injury, a resuscitation step is necessary to recondition the cells. Antioxidants have been shown to inhibit damage associated with active oxygen species. For example, pyruvate and other alphaketoacids have been reported to react rapidly and stoichiometrically with hydrogen peroxide to protect cells from cytolytic effects, O'Donnell-Tormey et al.. J. Exp. Med.. 165. pp. 500-514 (1987).
United States Patent No. 5,210,098 issued to Nath discloses a method to arrest or prevent acute kidney failure by administration of a non-toxic pyruvate salt to a patient in need of such treatment.
The Nath invention provides a therapeutic method comprising administration of an amount of pyruvate salt to a patient experiencing, or in danger of, acute renal failure. The pyruvate salt, preferably sodium pyruvate, is preferably dispersed or dissolved in a pharmaceutically acceptable liquid carrier and administered parenterally in an amount effective to arrest or prevent said acute renal failure, thus permitting restoration of normal kidney function. In some cases, the pyruvate may be infused directed into the kidney or into the proximal renal arterial circulation. The method is effective to prevent or counteract acute kidney failure due to a wide variety of causes, including, but not limited to, traumatic injury, including burn injury and obstruction; reperfusion following ischemia, inflammatory glomerulonephritis, and sepis, e.g. due to gram negative bacterial infection.
Martin et al.. 1994, United States patent no. 5,296,370, discloses therapeutic compositions for preventing and reducing injury to mammalian cells and increasing the resuscitation rate of injured mammalian cells. In one embodiment, the therapeutic composition comprises (a) pyruvate selected from the group consisting of pyruvic acid, pharmaceutically acceptable salts of pyruvic acid, and mixtures thereof, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids wherein the fatty acids are those fatty acids required for the resuscitation of injured mammalian cells.
United States Patent No. 5,256,697 issued to Miller et al.. discloses a method for orally administering a therapeutically effective amount of pyruvate precursor to a mammal to improve insulin resistance, lower lasting insulin levels and reduce fat gain.
United States patent nos. 3,920,835, 3,984,556, and 3,988,470, all issued to Van Scott et al. disclose methods for treating acne, dandruff, and palmar keratosis, respectively, which consist of applying to the affected area a topical composition comprising from about 1% to about 20% ofa lower aliphatic compound containing from two to six carbon atoms selected from the group consisting of alpha-hydroxyacids, alpha-ketoacids and esters thereof, and 3-hydroxybutryic acid in a pharmaceutically acceptable carrier. The aliphatic compounds include pyruvic acid and lactic acid.
United States patents nos. 4,105,783 and 4,197,316, both issued to Yu et al.. disclose a method and composition, respectively, for treating dry skin which consists of applying to the affected area a topical composition comprising from about 1% to about 20% ofa compound selected from the group consisting of amides and ammonium salts of alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier. The compounds include the amides and ammonium salts of pyruvic acid and lactic acid.
United States patent no.4,234,599, issued to Van Scott et al.. discloses a method for treating actinic and nonactinic skin keratoses which consists of applying to the affected area a topical composition comprising an effective amount of a compound selected from the group consisting of alpha-hydroxyacids, beta- hydroxyacids, and alpha-ketoacids in a pharmaceutically acceptable carrier. The acidic compounds include pyruvic acid and lactic acid.
United States patent no. 4,294,852, issued to Wildnauer et al.. discloses a composition for treating skin which comprises the alpha-hydroxyacids, beta-hydroxyacids, and alpha-ketoacids disclosed above by Van Scott et al. in combination with C3-C8 aliphatic alcohols.
United States patent no. 4,663,166, issued to Veech, discloses an electrolyte solution which comprises a mixture of L-lactate and pyruvate in a ratio from 20:1 to 1 :1, respectively, or a mixture of D-beta-hydroxybutyrate and acetoacetate, in a ratio from 6: 1 to 0.5:1 , respectively.
Sodium pyruvate has been reported to reduce the number of erosions, ulcers, and hemorrhages on the gastric mucosa in guinea pigs and rats caused by acetylsalicylic acid. The analgesic and antipyretic properties of acetylsalicylic acid were not impaired by sodium pyruvate, Puschmann, Arzneimittelforschung. 33. pp.
410-415 and 415-416 (1983).
Pyruvate has been reported to exert a positive inotropic effect in stunned myocardium, which is a prolonged ventricular dysfunction following brief periods of coronary artery occlusions which does not produce irreversible damage, Mentzer et al.. Ann.Sure.. 209. pp. 629-633 (1989).
Pyruvate has been reported to produce a relative stabilization of left ventricular pressure and work parameter and to reduce the size of infarctions. Pyruvate improves resumption of spontaneous beating ofthe heart and restoration of normal rates and pressure development, Bunger et al., J. Mol. Cell. Cardiol.. 18. pp. 423-438 (1986), Mochizuki et al.. J. Phvsiol. (Paris). 76, pp. 805-812 (1980), Regitz et al.. Cardiovasc. Res.. 15 pp. 652-658 (1981), Giannelli et al.. Ann.Thorac. Sure.. 21 pp. 386-396. (1976).
Sodium pyruvate has been reported to act as an antagonist to cyanide intoxication (presumably through the formation of cyanohydrin) and to protect against the lethal effects of sodium sulfide and to retard the onset and development of functional, moφhological, and biochemical measures of acrylamide neuropathy of axons, Schwartz et aL, Toxicol. Appl. Pharmacol., 50 pp. 437-442 ( 1979), Sabri et al. Brain Res.. 483. pp. 1-11 (1989). A chemotherapeutic cure of advanced L1210 leukemia has been reported using sodium pyruvate to restore abnormally deformed red blood cells to normal. The deformed red blood cells prevented adequate drug delivery to tumor cells. Cohen. Cancer Chemother. Pharmacol.. 5. pp. 175-179 (1981).
Primary cultures of heterotopic tracheal transplant exposed in vivo to 7, 12-dimethylbenz(a)anthracene were reported to be successfully maintained in enrichment medium supplemented with sodium pyruvate along with cultures of interleukin-2 stimulated peripheral blood lymphocytes, and plasmacytomas and hybridomas, pig embryos, and human blastocysts, Shacter, J. Immunol. Methods. 99. pp. 259-270 (1987). Marchok et al.. Cancer Res.. 37. pp. 181 1- 1821 ( 1977), Davis, J. Reprod. Fertil. Suppl.. 33. pp 1 15-124 (1985), Okamoto et al.. No To Shinkei. 38. pp. 593-598 ( 1986), Cohen et al.. J. In Vitro Fert. Embryo Transfer. 2, pp. 59-64 (1985).
United States patents nos. 4,158,057, 4,351,835, 4,415,576, and 4,645,764, all issued to Stanko, disclose methods for preventing the accumulation of fat in the liver ofa mammal due to the ingestion of alcohol, for controlling weight in a mammal, for inhibiting body fat while increasing protein concentration in a mammal, and for controlling the deposition of body fat in a living being, respectively. The methods comprise administering to the mammal a therapeutic mixture of pyruvate and dihydroxyacetone, and optionally riboflavin. United States patent no.4,548,937, issued to Stanko, discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of pyruvate, and optionally riboflavin. United States patent no 4,812,479, issued to Stanko, discloses a method for controlling the weight gain of a mammal which comprises administering to the mammal a therapeutically effective amount of dihydroxyacetone, and optionally riboflavin and pyruvate. Rats fed a calcium-oxalate lithogenic diet including sodium pyruvate were reported to develop fewer urinary calculi (stones) than control rats not given sodium pyruvate, Ogawa et al.. Hinvokika Kivo. 32, pp. 1341-1347 (1986).
United States patent no. 4,521,375, issued to Houlsby, discloses a method for sterilizing surfaces which come into contact with living tissue. The method comprises sterilizing the surface with aqueous hydrogen peroxide and then neutralizing the surface with pyruvic acid.
United States patent no. 4,416,982, issued to Tauda et al.. discloses a method for decomposing hydrogen peroxide by reacting the hydrogen peroxide with a phenol or aniline derivative in the presence of peroxidase.
United States patent no, 4,696,917, issued to Lindstrom et al., discloses an irrigation solution which comprises Eagle's Minimum Essential Medium with Earle's salts, chondroitin sulfate, a buffer solution, 2-mercaptoethanol, and a pyruvate. The irrigation solution may optionally contain ascorbic acid and alpha-tocopherol. United States patent no. 4,725,586, issued to Lindstrom et al.. discloses an irrigation solution which comprises a balanced salt solution, chondroitin sulfate, a buffer solution, 2 mercaptoethanol, sodium bicarbonate or dextrose, a pyruvate, a sodium phosphate buffer system, and cystine. The irrigation solution may optionally contain ascorbic acid and gamma-tocopherol.
United States patent no. 4,847,069, issued to Bissett et al.. discloses a photoprotective composition comprising (a) a sorbohydroxamic acid, (b) an anti¬ inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier. Fatty acids may be present as an emollient. United States patent no. 4,847,071, issued to Bissett et al.. discloses a photoprotective composition comprising (a) a tocopherol or tocopherol ester radical scavenger, (b) an anti-inflammatory agent selected from steroidal anti-inflammatory agents and a natural anti-inflammatory agent, and (c) a topical carrier. United States patent no. 4,847,072, issued to Bissett et al.. discloses a topical composition comprising not more than 25% tocopherol sorbate in a topical carrier.
The addition of sodium pyruvate to bacterial and yeast systems has been reported to inhibit hydrogen peroxide production, enhance growth, and protect the systems against the toxicity of reactive oxygen intermediates. The optimum ratio of unsaturated to saturated fatty acids contained within chicken fat enhanced membrane repair and reduced cytotoxicity. The antioxidants glutathione and thioglycollate reduced the injury induced by oxygen radical species, Martin, Ph.D. thesis, (1987 -89).
While the above therapeutic compositions and methods are reported to inhibit the production of reactive oxygen intermediates, none ofthe compositions and methods treats the damage and resulting disease state in mammals caused by undesired respiratory bursting, production of enzymes and cellular signaling agents in mammalian cells.
SUMMARY OF THE INVENTION
The present invention pertains to a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response and compositions useful in the method. The method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response comprises: contacting the mammalian cells participating in the inflammatory response with an inflammatory mediator; wherein the inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant. The inflammatory mediator in addition to reducing the undesired inflammatory response and being an antioxidant, may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. The inflammatory mediator may also increase cellular metabolic rate. The present invention also pertains to compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprising: An inflammatory response mediator; and a carrier composition; wherein the inflammatory response mediator is an antioxidant and capable of reducing undesired inflammatory response in mammalian cells.
The inflammatory response mediators may be used individually, in combination and further in combination with a therapeutic agent such as an antibacterial, antiviral, antifungal, protein, enzyme, antihistamine, hormone, nonsteroidal anti-inflammatory, cytokine, and steroid. A preferred method of administering the inflammatory mediator is by inhalation.
DETAILED DESCRIPTION OF THE INVENTION
Therapeutic compositions and a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response have been discovered. The mammalian cells primarily responsible for the inflammatory response are white blood cells or leucocytes.
In a method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response, mammalian cells are contacted with an inflammatory mediator. The inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant.
The inflammatory response, often referred to as respiratory bursting, is the response of defensive mammalian cells primarily white blood cells or leucocytes. These cells normally respond to an injury or invasion ofthe mammal by releasing a number of active compounds at the injury or invasion site. Among the compounds released are enzymes such as proteases and active oxygen species such as hydrogen peroxide.
A purpose ofthe respiratory burst is to provide a battery of oxidizing agents in response to a stimulant that can be used by the leucocytes for the destruction of foreign cells, viruses, particulates and some toxins which have been ingested by or are in the vicinity of the leucocyte. The term "respiratory burst" refers to a coordinated series of metabolic events that take place when leucocytes are exposed to appropriate stimuli. This group of events underlies all oxygen dependent killings by leucocytes.
The first of these events is the sharp increase in oxygen uptake that occurs upon stimulation ofthe leucocytes. While oxygen consumption by resting leucocytes varies widely by cell type, all respond to appropriate stimuli with an increase in oxygen uptake.
Stimulation of the leucocyte also causes an increase in glucose oxidation via the hexose monophosphate shunt. The hexose monophosphate shunt is a metabolic pathway in which glucose is oxidized to carbon dioxide and a five carbon sugar, with NADP+ serving as electron acceptor. Activation ofthe hexose monophosphate shunt therefore means that the oxidation of NADPH to NADP+ increases during the respiratory burst. The respiratory burst produces superoxide and hydrogen peroxide.
Oxygen taken up by the respiratory burst is converted to superoxide. Hydrogen peroxide appears to arise during the respiratory burst mainly from the dismutation of superoxide anion.
0-2 + O-2 + 2H+ H2 02 + 02 It has been demonstrated by Root and Metcalf and reported in J. Clin.
Invest. 60: 1266 that 80 percent ofthe superoxide is converted to hydrogen peroxide, and this dismutation reaction is the only important source of the hydrogen peroxide generated during the burst. Hydrogen peroxide and superoxide are believed to be responsible for the killing by leucocytes. Many agents, both soluble and particulate, are able to activate the respiratory burst. Particulate activating agents include bacteria, viruses and fungi for internal body organs or areas and bacteria, viruses, fungi, fibers, smoke, dust, ash, pollen, smog and the like for body cavities and organs such as the lungs, skin, digestive and excretory tracks open to the environment. Soluble agents can be toxins, medicinal compounds and soluble excretions of bacteria, fungi and infected mammalian cells and the like.
Activation of the respiratory burst in leucocytes usually follows exposure to the stimulus for less than a minute. Upon stimulation ofthe respiratory burst, the consumption of oxygen in leucocytes increases by over 100 fold resulting in, among other things, the production of superoxide, peroxide and hydrogen peroxide. The term "leucocytes" as used herein includes lymphocytes, phagocytes, macrophages and auxiliary cells.
Usually, after respiratory bursting the stimulant and/or the mechanism of stimulation turns off allowing the leucocyte to return to its normal resting state. When the bursting does not turn off, the inflammatory action of the leucocytes continues unchecked causing a number of disease states. These disease states occur as the compounds produced by the leucocytes attack, injure and kill tissue cells and other leucocytes. It is this failure to turn off the respiratory burst and the resulting injury to surrounding tissue cells, blood cells, other leucocytes and injured cells that produces the disease states treated by the present invention. Undesired inflammatory response occurs when the inflammatory response causes injury to host cells and this injury poses an independent threat to the host.
In a preferred embodiment, the therapeutic compositions containing an inflammatory mediator are administered locally to the site of inflammation. In another preferred embodiment, the therapeutic compositions are administered systemically. In yet another preferred embodiment, the therapeutic compositions are administered systemically and locally concomitantly.
In a preferred embodiment, the therapeutic compositions are administered by inhalation. The therapeutic compositions may be first nebulized by any suitable means. The therapeutic compositions may be in liquid or solid form with liquid droplets or particle size being small enough to facilitate access to lung tissue by inhalation.
In another preferred embodiment, a sterile solution of therapeutic agent is nebulized and inhaled by the patient. A therapeutically effective amount of inflammatory medication is inhaled. This may be accomplished in a single inhalation or by repeated inhalations over a period of time typically 1 to 30 minutes. Preferably, inhalation will be complete in less than 20 minutes. Most preferably inhalation will be complete in less than 15 minutes. The term "injured cell" as used herein means a cell which has some or all of the following: (a) injured membranes so that transport through the membranes is diminished and may result in one or more of the following, an increase in toxins and normal cellular wastes inside the cell and/or a decrease in nutrients and other components necessary for cellular repair inside the cell, (b) an increase in concentration of oxygen radicals inside the cell because ofthe decreased ability of the cell to produce antioxidants and enzymes, and (c) damaged DNA, RNA and ribosomes which must be repaired or replaced before normal cellular functions can be resumed. Preferably the inflammatory mediator when brought into contact with a mammalian cell provides a cellular energy source and a building block in the cellular synthesis of other cellular components.
The inflammatory response being reduced is at least one of the following: oxygen radical production, peroxide production, cytokine and/or protease production, prostiglandin production, erythema, histamine and interlukin production and like responses known in the art as inflammatory responses.
The preferred inflammatory mediator is at least one compound selected from the group consisting of a pyruvate precursor, pyruvate, a lactate precursor and lactate. A precursor is a substance from which another substance is formed and in this text also includes salts.
Preferably the pyruvate is selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and the like and mixtures thereof. Sodium pyruvate is most preferred. Another preferred inflammatory mediator is selected from the group consisting of pyruvy 1- gly cene, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, dihydroxyacetone, and propylene glycol.
Preferred salts of the inflammation mediator are salts that do not produce an adverse effect on the mammalian cell when applied as a salt of the inflammation mediator. Typical salts would be the lithium, sodium, potassium, aluminum, magnesium, calcium, zinc, manganese, ammonium and the like and mixtures thereof.
The lactate precursor is preferably selected from the group consisting of lactyl-glycene, lactyl-alanine, lactyl-leucine, lactyl-valine, lactyl-isoleucine, lactyl-phenylalanine, lactamide and the various salts of lactate.
Compositions for reducing and treating the disease state in mammals caused by undesired inflammatory response comprise: an inflammatory response mediator; and a carrier composition.
The carrier composition is selected from the group consisting of tablets, capsules, liquids, isotonic liquids, isotonic media, enteric tablets and capsules, parenterals, topicals, creams, gels, ointments, chewing gums, confections and the like. The inflammatory mediator is administered in a therapeutically effective amount to reduce the undesired inflammatory response. Preferably from 0.001 to 10 grams per dose. More preferably 0.001 to 1 gram per dose and most preferably 0.001 to 0.25 grams per dose. It is understood that the method of administration and the condition being treated will greatly affect the dose required to achieve the therapeutic effect.
Typical airway diseases treatable by the present compositions and method include but are not limited to bronchial asthma, acute bronchitis, emphysema, chronic obstructive emphysema, centrilobular emphysema, panacinar emphysema, chronic obstructive bronchitis, reactive airway disease, cystic fibrosis, bronchiectasis, acquired bronchiectasis, kartaagener's syndrome, atelectasis, acute atelectasis, chronic atelectasis, pneumonia, essential thrombocytopenia, legionnaires disease, psittacosis, fibrogenic dust disease, diseases due to organic dust, diseases due to irritant gases and chemicals, hypersensitivity diseases ofthe lung, idiopathic infiltrative diseases ofthe lungs and the like. Particular disease states to be treated are emphysema and asthma.
The inflammatory mediator of the present invention may be administered prior to, after and/or with other therapeutic agents. Typical therapeutic agents are antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti-inflammatories, cytokines, steroids, and the like. Obviously, numerous modifications and variations of the present invention are possible in the light ofthe above teachings and the invention is not limited to the example herein. It is therefore understood that within the scope ofthe appended claims, the invention may be practiced otherwise than as specifically described herein.
Example
Subject: A 59 year old male suffering from emphysema and restrictive airway disease was treated as described below for three (3) months. Prior to treatment the subject had limited capacity to breathe, did not respond to any other treatment, was on oxygen daily, and could not function at work (was on sabbatical leave). After three (3) months treatment he showed marked improvement. In fact, dramatic results were observed within two (2) weeks. Treatment: The treatment was conducted as follows: Five (5) milliliters of five (5) millimolar sodium pyruvate solution is filter sterilized through a 0.2 micron filter. The sterile pyruvate solution is placed into a "Pulmo Aid" nebulizer manufactured by DeVilbiss Co., Somerset, Pennsylvania 15501-0635. The sterile pyruvate solution is nebulized by the Pulmo Aid device fitted with a disposable nebulizer and inhaled by the patient. The patient inhales normally from the Pulmo Aid nebulizer until all of the solution has been nebulized and inhaled. This inhalation step typically takes about ten (10) to twenty (20) minutes.
The patient is treated with this inhalation therapy periodically. Initially, treatments are about four (4) times a day at about six (6) hour intervals. Treatments were reduced to three (3) times a day at about eight (8) hour intervals after 30 days of therapy. Treatments were further reduced to once a day 60 DAYS AFTER ONSET OF TREATMENT. After ninety (90) days treatments are three to five times a week.
The following data shows results of various lung capacity and lung function tests administered before treatment and two (2) months after treatment was commenced.
Before After Two
Tvpe of Test Treatment Months Treatment
SVC
(slow vital capacity) 63 83
IC
(inspiratory capacity) 64 69
ERV
(expiratory reserve volume) 62 110
MW
(maximum ventilatory volume) 19 25
DCO
(diffusion of carbon monoxide
Ml/min/mm Hg) 27 39
DSB
(diffusion single breath) 42 52
O SAT
(oxygen saturation) 91 95
Observation: Twenty to thirty minutes after initial treatment, tidal volume increases wheezing stops and an increase in exercise tolerance is observed. Reliance on "Proventil" (Albuterol made by Schering) is reduced from 1600 mg per day to 400 mg per day within the first two (2) weeks of treatment. Use of oxygen was eliminated immediately when treatment started.
Conclusion: Treatment did the following:
(1) Improved lung function by 20%. (2) Decreased some medication levels and ceased use of oxygen.
(3) Reactive airway disease is reduced to the point that routine use of inhalers is not needed.
(4) Increased exercise tolerance has been tested and certified as being close to that of a person without emphysema and restrictive airway disease. Subject has been able to return to full work schedule at previous job. (5) No recurrence of decreased pulmonary functions.
(6) Mental attitude has greatly improved.
While the method for treating the disease state in mammalian cells involved in the inflammatory response herein described constitute preferred embodiments of this invention, it is to be understood that the invention is not limited to this precise form of method and that changes may be made therein without departing from the scope ofthe invention which is defined in the appended claims.

Claims

I CLAIM:
1. A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response comprising: contacting the mammalian cells with an inflammatory mediator; wherein the inflammatory mediator is present in an amount capable of reducing the undesired inflammatory response and is an antioxidant.
2. The method of Claim 1 wherein the inflammatory mediator when brought into contact with a mammalian cell: provides a cellular energy source and a building block in the cellular synthesis of other cellular components.
3. The method of Claim 1 wherein the inflammatory response being reduced is at least one ofthe following: oxygen radical production, hydrogen peroxide production, cytokine and protease production, prostiglandin production, erythema, histamine and interlukin production.
4. The method of Claim 1 wherein the inflammatory mediator is at least one compound selected from the group consisting of: a pyruvate precursor, pyruvate, a lactate precursor and lactate.
5. The method of Claim 4 wherein the inflammatory mediator is pyruvate.
6. The method of Claim 4 wherein the pyruvate is selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, and mixtures thereof.
7. The method of Claim 4 wherein the inflammatory mediator is a pyruvate precursor.
8. The method of Claim 4 wherein the inflammatory mediator is a lactate precursor.
9. The method of Claim 4 wherein the inflammatory mediator is lactate.
10. The method of Claim 4, wherein the lactate is selected from the group consisting of lactic acid, lithium lactate, sodium lactate, potassium lactate, magnesium lactate, calcium lactate, zinc lactate, manganese lactate, and mixtures thereof.
11. The method of Claim 7 wherein the pyruvate precursor is selected from the group consisting of pyruvy 1-glycene, pyruvyl-alanine, pyruvyl- leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, dihydroxyacetone, propylene glycol and salts of pyruvic acid.
12. The method of Claim 8 wherein the lactate precursor is selected from the group consisting of lactyl-glycene, lactyl-alanine, lactyl-leucine, lactyl- valine, lacty 1-isoleucine, lactyl-phenylalanine, lactamide, and salts of lactic acid.
13. The method of Claim 1 wherein the disease state is an airway disease.
14. The method of Claim 13 wherein the airway disease is selected from the group comprising bronchial asthma, acute bronchitis, emphysema, chronic obstructive emphysema, centrilobular emphysema, panacinar emphysema, chronic obstructive bronchitis, reactive airway disease, cystic fibrosis, bronchiectasis, acquired bronchiectasis, kartaagener's syndrone, atelectasis, acute atelectasis, chronic atelectasis, pneumonia, essential thrombocytopenia, legionnaires disease, psittacosis, fibrogenic dust disease, diseases due to organic dust, diseases due to irritant gases and chemicals, hypersensitivity diseases of the lung, idiopathic infiltrative diseases ofthe lungs and the like.
15. The method of Claim 1 wherein the disease state is emphysema.
16. The method of Claim 1 wherein the disease state is asthma.
17. The method of Claim 1 further comprising contacting the mammalian cells with a therepeutic agent.
18. The method of claim 17 wherein the therapeutic agent is administered prior to the inflammatory mediator.
19. The method of Claim 17 wherein the therapeutic agent is administered concomitantly with administration ofthe inflammatory mediator.
20. The method of Claim 17 wherein the therapeutic agent is administered after administration ofthe inflammatory mediator.
21. The method of Claim 1 wherein the mammalian cells are white blood cells.
22. The method of Claim 17 wherein the therapeutic agent is one or more agents selected from the group consisting of antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti- inflammatories, cytokines, and steroids.
23. The method of Claim 2 wherein the inflammatory mediator increases cellular metabolic rate.
24. A composition for reducing and treating the disease state in mammals caused by undesired inflammatory response comprising: an inflammatory response mediator; and a carrier composition.
25. The composition of Claim 24 wherein the inflammatory mediator when brought into contact with a mammalian cell provides a cellular energy source and a building block in the cellular synthesis of other cellular components.
26. The composition of Claim 25 wherein the inflammatory mediator increases cellular metabolic rate.
27. The composition of Claim 24 wherein the carrier composition is an isotonic media.
28. The composition of Claim 24 wherein the inflammatory mediator is at least one compound selected from the group consisting of: pyruvate precursor, pyruvate, a lactate precursor and lactate.
29. The composition of Claim 28 wherein the inflammatory mediator is a pyruvate precursor.
30. The composition of Claim 29 wherein the pyruvate precursor is selected from the group consisting of pyruvy 1-glycene, pyruvy l-alanine, pyruvy 1- leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, dihydroxyacetone and propylene glycol.
31. The composition of Claim 27 wherein the inflammatory mediator is a lactate precursor.
32. The composition of Claim 31 wherein the lactate precursor is selected from the group consisting of lactyl-glycene, lactyl-alanine, lactyl-leucine, lactyl-valine, lactyl-isoleucine, lactyl-phenylalanine, lactamide and various salts of lactate.
33. The composition of Claim 28 wherein the inflammatory mediator is lactate.
34. The composition of Claim 24 wherein the carrier is selected from the group consisting of isotonic solutions, suspensions, and aerosols.
35. The composition of Claim 24 wherein the disease state is an airway disease.
36. The composition of Claim 24 wherein the disease state is emphysema.
37. The composition of Claim 24 wherein the disease state is asthma.
38. The composition of Claim 24 further comprising a therapeutic agent.
39. The composition of Claim 38 wherein the therapeutic agent is one or more agents selected from the group consisting of antibacterials, antivirals, antifungals, antihistamines, proteins, enzymes, hormones, nonsteroidal anti- inflammatories, cytokines, and steroids.
PCT/US1996/014304 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response WO1997010818A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX9703653A MX9703653A (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response.
JP51274197A JP4459303B2 (en) 1995-09-19 1996-09-06 Method of treating disease in mammals resulting from inflammatory reaction and composition thereof
CA002205112A CA2205112C (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response
AU69159/96A AU719332B2 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response
EP96929932A EP0804181A4 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response
NZ306832A NZ306832A (en) 1995-09-19 1996-09-06 Compositions for treating mammalian diseases caused by inflammatory response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US396295P 1995-09-19 1995-09-19
US60/003,962 1995-09-19

Publications (1)

Publication Number Publication Date
WO1997010818A1 true WO1997010818A1 (en) 1997-03-27

Family

ID=21708422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/014304 WO1997010818A1 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response

Country Status (10)

Country Link
EP (1) EP0804181A4 (en)
JP (1) JP4459303B2 (en)
AU (1) AU719332B2 (en)
CA (1) CA2205112C (en)
IL (1) IL119225A (en)
MX (1) MX9703653A (en)
NZ (1) NZ306832A (en)
TW (1) TW434012B (en)
WO (1) WO1997010818A1 (en)
ZA (1) ZA967833B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1463496A4 (en) * 2001-08-21 2005-01-26 Cellular Sciences Inc Method for treating bronchial constriction and bronchospam
EP1429712A4 (en) * 2001-08-21 2005-12-14 Cellular Sciences Inc Method for treating bronchial constriction and bronchospasm
EP1379230A4 (en) * 2001-03-15 2009-01-21 Univ Pittsburgh METHOD OF USE OF PYRUVATE AND / OR ITS DERIVATIVES FOR TREATING CYTOKINE-ORGANIZED INFLAMMABLE CONDITIONS
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
WO2018232383A1 (en) * 2017-06-16 2018-12-20 Vanderbilt University Methods and compositions for treating microbial inflammation
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation
WO2021094341A1 (en) * 2019-11-14 2021-05-20 Merck Patent Gmbh Cell culture media
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069431A1 (en) * 1999-05-14 2000-11-23 Cellular Sciences, Inc. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
WO2009116546A1 (en) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 Excitatory chemical mediator and method for screening thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1857M (en) * 1962-03-08 1963-06-10 Roussel Uclaf New drug in particular for the treatment of diseases of viral origin.
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4521375A (en) * 1982-11-23 1985-06-04 Coopervision, Inc. Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof
DE3302694A1 (en) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München ORAL CARE PRODUCTS
DE3586844T2 (en) * 1984-06-22 1994-03-17 Richard L Veech ELECTROLYTE SOLUTIONS AND THEIR USE (IN VIVO).
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
JPS63135370A (en) * 1986-11-26 1988-06-07 Grelan Pharmaceut Co Ltd Antiallergic agent
IN168530B (en) * 1987-11-06 1991-04-20 Lyphomed Inc
AU4056089A (en) * 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
JP2794021B2 (en) * 1988-11-02 1998-09-03 エーザイ株式会社 Transdermal preparation containing azelastine or its salts
JPH04506363A (en) * 1990-03-30 1992-11-05 アムジエン・インコーポレーテツド respiratory burst inhibitor
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
CA2129732A1 (en) * 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
JP3236658B2 (en) * 1992-04-27 2001-12-10 花王株式会社 Bronchodilator
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 101, 1984, (Columbus, OH, USA), the Abstract No. 157486, THEILEMANN, H., "Composition for Mouth Care"; & DE,A,3 302 694 (Ger). *
CHEMICAL ABSTRACTS, Vol. 124, 1996, (Columbus, OH, USA), the Abstract No. 212140, MARTIN, A., "Anti-Inflammatory Wound Healing Compositions Containing Pyruvates and Antioxidants and Fatty Acids"; & WO,A,96 00584. *
See also references of EP0804181A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379230A4 (en) * 2001-03-15 2009-01-21 Univ Pittsburgh METHOD OF USE OF PYRUVATE AND / OR ITS DERIVATIVES FOR TREATING CYTOKINE-ORGANIZED INFLAMMABLE CONDITIONS
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1463496A4 (en) * 2001-08-21 2005-01-26 Cellular Sciences Inc Method for treating bronchial constriction and bronchospam
EP1429712A4 (en) * 2001-08-21 2005-12-14 Cellular Sciences Inc Method for treating bronchial constriction and bronchospasm
AU2002323191B2 (en) * 2001-08-21 2007-07-19 Cellular Sciences, Inc. Method for treating bronchial constriction and bronchospasm
EP1427402A4 (en) * 2001-08-21 2007-12-05 Cellular Sciences Inc Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
CN104998264B (en) * 2005-02-11 2020-09-15 北方细胞制药公司 Methods and compositions for treating mammalian diseases and wounds caused by peroxynitrite overexpression
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
WO2018232383A1 (en) * 2017-06-16 2018-12-20 Vanderbilt University Methods and compositions for treating microbial inflammation
US11771739B2 (en) 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation
WO2021058428A1 (en) * 2019-09-24 2021-04-01 Evonik Operations Gmbh Compositions for use in reducing inflammation
WO2021094341A1 (en) * 2019-11-14 2021-05-20 Merck Patent Gmbh Cell culture media

Also Published As

Publication number Publication date
EP0804181A4 (en) 2005-02-02
JP4459303B2 (en) 2010-04-28
NZ306832A (en) 2001-04-27
EP0804181A1 (en) 1997-11-05
JPH10509463A (en) 1998-09-14
IL119225A (en) 2000-09-28
IL119225A0 (en) 1996-12-05
CA2205112A1 (en) 1997-03-27
CA2205112C (en) 2008-11-18
ZA967833B (en) 1997-06-02
AU719332B2 (en) 2000-05-04
MX9703653A (en) 1998-07-31
AU6915996A (en) 1997-04-09
TW434012B (en) 2001-05-16

Similar Documents

Publication Publication Date Title
US20060247308A1 (en) Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US5798388A (en) Method and composition for treating mammalian diseases caused by inflammatory response
AU2006213755B2 (en) Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US6689810B2 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP0792163B1 (en) Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
AU2002329762A1 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
WO1993010776A1 (en) Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
AU719332B2 (en) Method and composition for treating mammalian diseases caused by inflammatory response
US7122578B2 (en) Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
JP2011190274A (en) Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20040220265A1 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
CZ20021559A3 (en) Use of dinitrogen dioxide for producing a medicament intended for treating airways constriction
AU674131C (en) Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

ENP Entry into the national phase

Ref document number: 2205112

Country of ref document: CA

Ref country code: CA

Ref document number: 2205112

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996929932

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996929932

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642